Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

K. Yoshida; B. Sun; L. Zhang; P. Zhao; D. R. Abernethy; T. D. Nolin; A. Rostami-Hodjegan; I. Zineh; S. M. Huang

doi:10.1002/cpt.337

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

K. Yoshida, B. Sun, L. Zhang, P. Zhao, D. R. Abernethy, T. D. Nolin, A. Rostami-Hodjegan, I. Zineh, S. M. Huang

School of Medicine

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated. In this study we developed a comprehensive dataset of the effect of CKD on the pharmacokinetics of CYP2D6- and CYP3A4/5-metabolized drugs. Drugs for evaluation were selected based on clinical drug-drug interaction (CYP3A4/5 and CYP2D6) and pharmacogenetic (CYP2D6) studies. Information from dedicated CKD studies was available for 13 and 18 of the CYP2D6 and CYP3A4/5 model drugs, respectively. Analysis of these data suggested that CYP2D6-mediated clearance is generally decreased in parallel with the severity of CKD. There was no apparent relationship between the severity of CKD and CYP3A4/5-mediated clearance. The observed elimination-route dependency in CKD effects between CYP2D6 and CYP3A4/5 may inform the need to conduct clinical CKD studies with nonrenally eliminated drugs for optimal use of drugs in patients with CKD.

Original language	English (US)
Pages (from-to)	75-87
Number of pages	13
Journal	Clinical pharmacology and therapeutics
Volume	100
Issue number	1
DOIs	https://doi.org/10.1002/cpt.337
State	Published - Jul 1 2016

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt.337

Cite this

@article{9a620ba360db48c48e0772ac59c3af3a,

title = "Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5",

abstract = "Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated. In this study we developed a comprehensive dataset of the effect of CKD on the pharmacokinetics of CYP2D6- and CYP3A4/5-metabolized drugs. Drugs for evaluation were selected based on clinical drug-drug interaction (CYP3A4/5 and CYP2D6) and pharmacogenetic (CYP2D6) studies. Information from dedicated CKD studies was available for 13 and 18 of the CYP2D6 and CYP3A4/5 model drugs, respectively. Analysis of these data suggested that CYP2D6-mediated clearance is generally decreased in parallel with the severity of CKD. There was no apparent relationship between the severity of CKD and CYP3A4/5-mediated clearance. The observed elimination-route dependency in CKD effects between CYP2D6 and CYP3A4/5 may inform the need to conduct clinical CKD studies with nonrenally eliminated drugs for optimal use of drugs in patients with CKD.",

author = "K. Yoshida and B. Sun and L. Zhang and P. Zhao and Abernethy, {D. R.} and Nolin, {T. D.} and A. Rostami-Hodjegan and I. Zineh and Huang, {S. M.}",

note = "Publisher Copyright: {\textcopyright} 2015 The American Society for Clinical Pharmacology and Therapeutics.",

year = "2016",

month = jul,

day = "1",

doi = "10.1002/cpt.337",

language = "English (US)",

volume = "100",

pages = "75--87",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

AU - Yoshida, K.

AU - Sun, B.

AU - Zhang, L.

AU - Zhao, P.

AU - Abernethy, D. R.

AU - Nolin, T. D.

AU - Rostami-Hodjegan, A.

AU - Zineh, I.

AU - Huang, S. M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated. In this study we developed a comprehensive dataset of the effect of CKD on the pharmacokinetics of CYP2D6- and CYP3A4/5-metabolized drugs. Drugs for evaluation were selected based on clinical drug-drug interaction (CYP3A4/5 and CYP2D6) and pharmacogenetic (CYP2D6) studies. Information from dedicated CKD studies was available for 13 and 18 of the CYP2D6 and CYP3A4/5 model drugs, respectively. Analysis of these data suggested that CYP2D6-mediated clearance is generally decreased in parallel with the severity of CKD. There was no apparent relationship between the severity of CKD and CYP3A4/5-mediated clearance. The observed elimination-route dependency in CKD effects between CYP2D6 and CYP3A4/5 may inform the need to conduct clinical CKD studies with nonrenally eliminated drugs for optimal use of drugs in patients with CKD.

AB - Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated. In this study we developed a comprehensive dataset of the effect of CKD on the pharmacokinetics of CYP2D6- and CYP3A4/5-metabolized drugs. Drugs for evaluation were selected based on clinical drug-drug interaction (CYP3A4/5 and CYP2D6) and pharmacogenetic (CYP2D6) studies. Information from dedicated CKD studies was available for 13 and 18 of the CYP2D6 and CYP3A4/5 model drugs, respectively. Analysis of these data suggested that CYP2D6-mediated clearance is generally decreased in parallel with the severity of CKD. There was no apparent relationship between the severity of CKD and CYP3A4/5-mediated clearance. The observed elimination-route dependency in CKD effects between CYP2D6 and CYP3A4/5 may inform the need to conduct clinical CKD studies with nonrenally eliminated drugs for optimal use of drugs in patients with CKD.

UR - http://www.scopus.com/inward/record.url?scp=84960172967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960172967&partnerID=8YFLogxK

U2 - 10.1002/cpt.337

DO - 10.1002/cpt.337

M3 - Article

C2 - 26800425

AN - SCOPUS:84960172967

SN - 0009-9236

VL - 100

SP - 75

EP - 87

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 1

ER -

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this